Palantir (PLTR) Stock Under Scrutiny as UK Lawmakers Demand NHS Contract Exit

Key Takeaways

• British parliamentary report identifies Palantir dependency as an “unacceptable point of weakness” for national security
• Lawmakers highlight the £330 million ($444 million) NHS data platform agreement as creating dangerous vendor dependency
• Report references Peter Thiel’s political connections and Palantir’s defense sector involvement as incompatible with British principles
• Parliamentary committee recommends activating the 2027 contract exit provision and pursuing domestic alternatives
• Palantir’s British leadership dismissed cancellation calls as “frankly irresponsible”

British lawmakers have issued a sharp rebuke of Palantir’s expanding presence in UK government operations, expressing alarm that reliance on the American data analytics company creates vulnerabilities around sensitive public information.

Palantir Technologies Inc., PLTR

On Wednesday, the Commons Science, Innovation and Technology Committee released a comprehensive 70-page assessment that highlighted Palantir as a concerning case study of excessive dependence on a limited group of American technology vendors. The assessment characterized this dependency as an “unacceptable point of weakness.”

Shares of Palantir (PLTR) drew attention after the parliamentary report emerged, as market participants monitored potential implications from mounting political opposition in a strategically important overseas market.

Central to the committee’s concerns is Palantir’s seven-year National Health Service arrangement valued at £330 million. Secured in 2023, the agreement aims to consolidate healthcare information from throughout the NHS into a unified system enabling medical professionals to make more informed, timely decisions.

According to NHS officials, the partnership has produced “huge benefits for patients,” including accelerated cancer identification and the treatment of thousands of additional patients monthly.

Lawmakers Push for 2027 Contract Termination

Despite these reported advantages, the parliamentary committee is pressing the government to invoke a contractual exit provision available in 2027. The recommendation includes transitioning to a British-based solution or developing an internal capability.

Beyond technical considerations, MPs expressed concerns about aspects of Palantir’s profile and leadership. The assessment referenced co-founder Peter Thiel’s relationships with Donald Trump and his previous critiques of public healthcare systems. Additionally, the report noted Palantir’s contracts providing technology to American defense and immigration enforcement agencies.

The committee concluded these factors constitute a “clear mismatch with UK values” and cautioned that Britain’s digital modernization objectives could be “derailed at any time by a decision taken outside our shores.”

Committee chair Dame Chi Onwurah stated the UK faces serious exposure and advocated for technological independence in essential public service domains.

Company Defends NHS Partnership

Louis Mosley, Palantir’s UK chief executive, responded swiftly to the criticism. In a BBC radio interview, he noted the committee itself had recognized the NHS contract’s positive performance, making termination calls “frankly irresponsible.”

Mosley emphasized that Palantir secured the agreement through a transparent, competitive procurement procedure, and that NHS data governance remains entirely with the health service.

Foxglove, a British advocacy organization that has actively opposed Palantir’s NHS participation, praised the parliamentary findings and urged complete contract termination.

The committee’s assessment also criticized broader government digital initiatives, characterizing the administration’s £45 billion annual savings target through digitalization as “worryingly optimistic.”

Additional recommendations included designating a cabinet-level minister specifically responsible for overseeing digital transformation efforts.

The UK government’s Department of Health and Social Care had not issued a statement in response to the report at press time.